IFN-γ | Fold vs Control ± SE (n = 3) | |||
---|---|---|---|---|
Doses (nM) | ||||
1 | 10 | 100 | 1000 | |
Retinoid | ||||
ATRA | 0.63 ± 0.04 | 0.61 ± 0.05 | 0.43 ± 0.13 | 0.38 ± 0.10 |
9-cis-RA | 0.76 ± 0.06 | 0.38 ± 0.09 | 0.32 ± 0.06 | 0.30 ± 0.05 |
13-cis-RA | 0.64 ± 0.11 | 0.59 ± 0.04 | 0.53 ± 0.04 | 0.47 ± 0.09 |
4-HPR | 0.83 ± 0.11 | 0.75 ± 0.07 | 0.73 ± 0.02 | 0.65 ± 0.03 |
2-way ANOVA | ||||
Dose | p = 0.0001 | |||
Retinoid | p < 0.0001 | |||
Tukey Kramer | ||||
Dose | p < 0.01 | 1 nM vs 100 nM | ||
1 nM vs 1000 nM | ||||
Retinoid | p < 0.01 | 4-HPR vs ATRA | ||
4-HPR vs 9-cis RA | ||||
4-HPR vs 13-cis RA | ||||
IL-12p70 | Fold vs Control ± SE (n = 3) | |||
Dose (nM) | ||||
1 | 10 | 100 | 1000 | |
Retinoid | ||||
ATRA | 0.57 ± 0.18 | 0.40 ± 0.11 | 0.36 ± 0.13 | 0.27 ± 0.12 |
9-cis-RA | 1.0 ± 0.12 | 0.39 ± 0.07 | 0.25 ± 0.19 | 0.21 ± 0.09 |
13-cis-RA | 1.1 ± 0.29 | 0.61 ± 0.20 | 0.42 ± 0.14 | 0.41 ± 0.09 |
4-HPR | 1.2 ± 0.47 | 1.2 ± 0.41 | 0.94 ± 0.26 | 0.84 ± 0.16 |
2-way ANOVA | ||||
Dose | p = 0.004 | |||
Retinoid | p = 0.0007 | |||
Tukey Kramer | ||||
Dose | p < 0.05 | 1 nM vs 100 nM | ||
p < 0.01 | 1 nM vs 1000 nM | |||
Retinoid | p < 0.01 | 4-HPR vs ATRA | ||
4-HPR vs 9-cis-RA | ||||
p < 0.01 | 4-HPR vs 13-cis-RA |